CYTOR could activate Hippo and MAPK pathways via regulation of miR‐125a‐5p to enhance breast cancer cell survival upon tamoxifen treatment, indicating that targeting CYTOR may be a possible approach in reversing tamoxifen resistance in breast cancer.50 The gene discussed is CYTOR; the disease is breast carcinoma.